Royal Bank of Canada’s BioLineRX BLRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-505
| Closed | -$4K | – | 6823 |
|
|
2024
Q4 | $4K | Buy |
+505
| New | +$7.45K | ﹤0.01% | 6568 |
|
|
2024
Q3 | – | Sell |
-2
| Closed | – | – | 6862 |
|
|
2024
Q2 | $0 | Hold |
2
| – | – | ﹤0.01% | 7063 |
|
|
2024
Q1 | $0 | Hold |
2
| – | – | ﹤0.01% | 7022 |
|
|
2023
Q4 | $0 | Sell |
2
-49
| -96% | -$3.03K | ﹤0.01% | 7121 |
|
|
2023
Q3 | $4K | Hold |
51
| – | – | ﹤0.01% | 6646 |
|
|
2023
Q2 | $3K | Hold |
51
| – | – | ﹤0.01% | 6776 |
|
|
2023
Q1 | $2K | Hold |
51
| – | – | ﹤0.01% | 6751 |
|
|
2022
Q4 | $1K | Hold |
51
| – | – | ﹤0.01% | 7002 |
|
|
2022
Q3 | $2K | Hold |
51
| – | – | ﹤0.01% | 6988 |
|
|
2022
Q2 | $3K | Hold |
51
| – | – | ﹤0.01% | 6805 |
|
|
2022
Q1 | $3K | Buy |
51
+49
| +2,450% | +$3.41K | ﹤0.01% | 7375 |
|
|
2021
Q4 | $0 | Hold |
2
| – | – | ﹤0.01% | 7651 |
|
|
2021
Q3 | $0 | Hold |
2
| – | – | ﹤0.01% | 7629 |
|
|
2021
Q2 | $0 | Hold |
2
| – | – | ﹤0.01% | 7481 |
|
|
2021
Q1 | $0 | Hold |
2
| – | – | ﹤0.01% | 7423 |
|
|
2020
Q4 | $0 | Sell |
2
-3
| -60% | -$262 | ﹤0.01% | 7061 |
|
|
2020
Q3 | $0 | Hold |
5
| – | – | ﹤0.01% | 6621 |
|
|
2020
Q2 | $0 | Hold |
5
| – | – | ﹤0.01% | 6625 |
|
|
2020
Q1 | $0 | Hold |
5
| – | – | ﹤0.01% | 6674 |
|
|
2019
Q4 | $0 | Hold |
5
| – | – | ﹤0.01% | 6822 |
|
|
2019
Q3 | $0 | Hold |
5
| – | – | ﹤0.01% | 6702 |
|
|
2019
Q2 | $1K | Hold |
5
| – | – | ﹤0.01% | 6677 |
|
|
2019
Q1 | $1K | Hold |
5
| – | – | ﹤0.01% | 6616 |
|
|
2018
Q4 | $1K | Hold |
5
| – | – | ﹤0.01% | 6546 |
|
|
2018
Q3 | $3K | Hold |
5
| – | – | ﹤0.01% | 6400 |
|
|
2018
Q2 | $3K | Hold |
5
| – | – | ﹤0.01% | 6152 |
|
|
2018
Q1 | $3K | Buy |
5
+3
| +150% | +$1.84K | ﹤0.01% | 6039 |
|
|
2017
Q4 | $1K | Sell |
2
-3
| -60% | -$1.98K | ﹤0.01% | 6364 |
|
|
2017
Q3 | $3K | Hold |
5
| – | – | ﹤0.01% | 6504 |
|
|
2017
Q2 | $3K | Hold |
5
| – | – | ﹤0.01% | 6177 |
|
|
2017
Q1 | $3K | Sell |
5
-2
| -29% | -$1.29K | ﹤0.01% | 6336 |
|
|
2016
Q4 | $4K | Hold |
7
| – | – | ﹤0.01% | 6344 |
|
|
2016
Q3 | $4K | Hold |
7
| – | – | ﹤0.01% | 6013 |
|
|
2016
Q2 | $4K | Hold |
7
| – | – | ﹤0.01% | 5995 |
|
|
2016
Q1 | $4K | Buy |
7
+2
| +40% | +$1.26K | ﹤0.01% | 5961 |
|
|
2015
Q4 | $4K | Hold |
5
| – | – | ﹤0.01% | 6206 |
|
|
2015
Q3 | $5K | Hold |
5
| – | – | ﹤0.01% | 6152 |
|
|
2015
Q2 | $8K | Buy |
5
+2
| +67% | +$2.48K | ﹤0.01% | 6121 |
|
|
2015
Q1 | $4K | Hold |
3
| – | – | ﹤0.01% | 5785 |
|
|
2014
Q4 | $3K | Hold |
3
| – | – | ﹤0.01% | 5899 |
|
|
2014
Q3 | $3K | Sell |
3
-17
| -85% | -$18.3K | ﹤0.01% | 5731 |
|
|
2014
Q2 | $25K | Hold |
20
| – | – | ﹤0.01% | 5116 |
|
|
2014
Q1 | $27K | Hold |
20
| – | – | ﹤0.01% | 5085 |
|
|
2013
Q4 | $34K | Hold |
20
| – | – | ﹤0.01% | 5049 |
|
|
2013
Q3 | $27K | Hold |
20
| – | – | ﹤0.01% | 5065 |
|
|
2013
Q2 | $19K | Buy |
+20
| New | +$20.7K | ﹤0.01% | 5040 |
|
Other funds holding BLRX
NRG
NA
Royal Bank of Canada's BLRX Position: Q1 2025 in Review
Royal Bank of Canada sold out of BioLineRX (BLRX) in Q1 2025, closing a stake of 505 shares — an estimated $4K sold.
Royal Bank of Canada first reported a position in BLRX in Q2 2013 and held it in 46 quarters. The position peaked at $34K in Q4 2013. 12 funds tracked by Wall St. Rank hold BLRX as of Q1 2025.
- Royal Bank of Canada reported no remaining BioLineRX position as of Q1 2025 after selling out during the quarter.
- Royal Bank of Canada sold 505 BioLineRX shares in Q1 2025, an estimated $4K.
- Royal Bank of Canada first reported a position in BioLineRX in Q2 2013 and held it in 46 quarters.
- Royal Bank of Canada's BioLineRX position peaked at $34K in Q4 2013.
- 12 funds tracked by Wall St. Rank held BioLineRX as of Q1 2025.
Based on Royal Bank of Canada's 13F filing for Q1 2025, filed 15 May 2025.